Reduced telomeric signals and increased telomeric associations in human lung cancer cell lines undergoing p53-mediated apoptosis

被引:21
作者
Mukhopadhyay, T
Multani, AS
Roth, JA
Pathak, S
机构
[1] Univ Texas, MD Anderson Cancer Ctr, Dept Thorac & Cardiovasc Surg, Sect Thorac Mol Oncol, Houston, TX 77030 USA
[2] Univ Texas, MD Anderson Cancer Ctr, Dept Cell Biol, Houston, TX 77030 USA
关键词
p53; lung cancer; apoptosis; telomere; gene expression;
D O I
10.1038/sj.onc.1202011
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Transduction of a p53-negative H1299 human non-small cell lung cancer cell line with an adenoviral vector containing wild-type p53 (Ad5p53) induced apoptosis, Analysis of the Ad5p53-infected H1299 cells showed high levels of telomeric association prior to apoptotic nuclear fragmentation. Similar telomeric association was observed in stably transfected clones of the wtH226b cell line, which expressed exogenous wild-type p53 protein and also showed complex chromosomal abnormalities including dicentrics, rings and fragments, Fluorescence ill situ hybridization (FISH) analysis using a human telomeric DNA probe indicated reductions in telomere signals in both Ad5p53-infected H1299 cells and wtH226b-S cells. In contrast, stably transfected wtH226b-AS clones expressing antisense p53 cDNA showed no telomeric association and had high levels of telomeric signals associated with a faster growing phenotype, These results suggest that wild-type p53 is involved in shortening telomeres, a possibly early event in the p53-mediated apoptotic process and in the subsequent telomeric association that predisposes a cell to genetic instability and DNA fragmentation resulting in apoptotic cell death. Moreover, loss of telomeric signals may indicate a cell's decision to undergo programmed cell death and, if so, could, serve as a sensitive marker of p53-mediated apoptosis.
引用
收藏
页码:901 / 906
页数:6
相关论文
共 24 条
[21]   WILD-TYPE P53 INDUCES APOPTOSIS OF MYELOID LEUKEMIC-CELLS THAT IS INHIBITED BY INTERLEUKIN-6 [J].
YONISHROUACH, E ;
RESNITZKY, D ;
LOTEM, J ;
SACHS, L ;
KIMCHI, A ;
OREN, M .
NATURE, 1991, 352 (6333) :345-347
[22]  
YONISHROUACH E, 1996, ONCOGENE, V12, P2197
[23]   SAFETY EVALUATION OF AD5CMV-P53 IN-VITRO AND IN-VIVO [J].
ZHANG, WW ;
ALEMANY, R ;
WANG, JX ;
KOCH, PE ;
ORDONEZ, NG ;
ROTH, JA .
HUMAN GENE THERAPY, 1995, 6 (02) :155-164
[24]  
ZHANG WW, 1993, BIOTECHNIQUES, V15, P868